Search hospitals > Michigan > Lansing
Sparrow Regional Cancer Center
Claim this profileLansing, Michigan 48912
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Solid Tumors
222 reported clinical trials
6 medical researchers
Summary
Sparrow Regional Cancer Center is a medical facility located in Lansing, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Solid Tumors and other specialties. Sparrow Regional Cancer Center is involved with conducting 222 clinical trials across 204 conditions. There are 6 research doctors associated with this hospital, such as John Ip, Nam Cho, MD, Gaurav Dhar, and Joel Cohn, MD.Area of expertise
1Breast Cancer
Global LeaderStage II
Stage I
Stage III
2Lung Cancer
Global LeaderTop PIs
John IpSparrow Clinical Research Institute2 years of reported clinical research
Studies Heart Failure
Studies Slow Heart Rate
6 reported clinical trials
7 drugs studied
Nam Cho, MDSparrow Clinical Research Institute6 years of reported clinical research
Studies Stroke
Studies Aortic Valve Stenosis
5 reported clinical trials
8 drugs studied
Gaurav DharUAMS Medical Center6 years of reported clinical research
Studies Stroke
Studies Patent Foramen Ovale
3 reported clinical trials
4 drugs studied
Joel Cohn, MDSparrow Clinical Research Institute5 years of reported clinical research
Studies Pathologic Constriction
Studies Carotid Stenosis
2 reported clinical trials
6 drugs studied
Clinical Trials running at Sparrow Regional Cancer Center
Aortic Valve Stenosis
Patent Foramen Ovale
Kidney Disease
Atrial Fibrillation
Syndrome
Acute Coronary Syndrome
Aortic Stenosis
Coronary Artery Stenosis
Coronary Heart Disease
Myocardial Ischemia
PCI vs Medical Management
for Aortic Stenosis
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
Recruiting1 award N/A4 criteria
Portico Valve
for Aortic Stenosis
This trial is testing a new heart valve replacement device for patients with severe heart valve issues who are too high-risk for traditional surgery. The device is inserted through a blood vessel, making the procedure less invasive.
Recruiting1 award N/A9 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sparrow Regional Cancer Center?
Sparrow Regional Cancer Center is a medical facility located in Lansing, Michigan. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Solid Tumors and other specialties. Sparrow Regional Cancer Center is involved with conducting 222 clinical trials across 204 conditions. There are 6 research doctors associated with this hospital, such as John Ip, Nam Cho, MD, Gaurav Dhar, and Joel Cohn, MD.